A new acquisition by Profound Medical Corp. (TSXV:PRN) has Echelon Wealth Partners analyst Doug Loe feeling bullish about the company’s stock. Last week, Profound Medical announced it would acquire the Sonalleve MR-HIFU business from partner Royal Philips for 7.4-million shares priced at $1.10, plus earnout provisions. Sonalleve is a magnetic resonance technology used in a […]
The Cantech Letter Life Sciences section is brought to you by RepliCel Life Sciences (TSXV:RP). RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address conditions linked to a deficit of healthy cells required for normal healing and function. Click on the logo above for more info.
New FDA sterilization rules will push hospitals to TSO3, says Canaccord Genuity
Strict new FDA requirements are making TSO3 (TSX:TOS) look like a winner, says Canaccord Genuity analyst Neil Maruoka. Earlier this month, in response to various superbug outbreaks it blamed on issues with reprocessing certain medical devices, the U.S. Food and Drug Administration released a list of devices that the agency will require validated instructions for […]
Valeant Pharma’s addition of Paulson to board gets thumbs up at Canaccord Genuity
The addition of a respected board member is a positive, but Valeant Pharmaceuticals (TSX,NYSE:VRX) still faces a number of challenges, says Canaccord Genuity analyst Neil Maruoka. Yesterday, Valeant announced that John Paulson, president of New York-based investment firm Paulson & Company, would join its board as the 11th member. “The strategic plan to transform Valeant […]
CEO departure is bad timing for Medical Facilities Corp, says Canaccord Genuity
An abrupt exit for its CEO has left Canaccord Genuity analyst Neil Maruoka wondering just how deep Medical Facilities Corp’s (TSX:DR) bench is. Yesterday, Medical Facilities Corp. announced its president and chief executive officer Britt T. Reynolds left the corporation and resigned as a member of the board. The company said board member Jeffrey Lozon […]
Eden Rahim: here’s the real problem with Valeant Pharma’s restructuring
The markets last week cheered Valeant Pharmaceuticals’ (TSX,NYSE:VRX) latest move to reduce its debt, sending shares Thursday up by nearly ten per cent. But one expert says the company’s restructuring efforts may not, in fact, be having the positive effect many think. On Thursday, This morning, Valeant Pharma announced it would sell its iNova Pharmaceuticals […]
Valeant Pharma gets price target raise at Canaccord Genuity
Canaccord Genuity analyst Neil Maruoka says the sale of iNova Pharma is a solid strategic move, but it is one that doesn’t cover the challenges that remain at Valeant Pharmaceuticals (TSX, NYSE:VRX). This morning, Valeant announced it would sell its iNova Pharmaceuticals business to funds advised and managed by Pacific Equity Partners and The Carlyle […]
Paradigm Capital: we have a “positive bias” towards ProMetic Life Sciences
A new analyst covering ProMetic Life Sciences (TSX:PLI) at Paradigm Capital means a new angle, but analyst Rahul Sarugaser says he maintains the firm’s “positive bias” on the stock. In a research update to clients today, analyst Rahul Sarugaser assumed Paradigm Capital’s coverage of ProMetic Life Sciences, placing the firm’s “Buy” rating and one-year price […]
Canadian breast cancer screening slammed in new Harvard Medical School article
A new article on the groundbreaking Canadian National Breast Screening Study argues that the study used unscientific methods as well as “poor quality” mammography equipment, both of which effectively compromised the process and rendered the results unreliable. Penned by Dr. Daniel Kopans of the Breast Imaging Division at Harvard Medical School, the article says contrary […]
Buy Medicure on weakness, says M Partners
Ahead of the company’s Q1, 2017 results, M Partners analyst Steven Salz thinks Medicure (TSX:MPH) is undervalued. On Wednesday, Medicure will report its first quarter results. Salz thinks the company will post fully diluted earnings of $0.09 and EBITDA of $4.0-million on revenue of $12.3-million. The street consensus has the company earning $0.04 and posting […]
Helius Medical Technologies is undervalued, says Mackie Research
Following the company’s fourth quarter results, Mackie Research Capital analyst André Uddin is still bullish on Helius Medical Technologies (TSX:HSM). Yetserday, Helius reported its fourth quarter results. The company lost (USD) $5.7-million on zero revenue, a result that compared unfavorably to last year’s Q4 loss of $3.8-million, also on zero revenue. Uddin says that though […]
- 1
- 2
- 3
- …
- 69
- Next Page »